Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.39 USD | +4.51% | -14.72% | -87.50% |
May. 16 | Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding | CI |
May. 14 | Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance | MT |
Financials (USD)
Sales 2022 | - | Sales 2023 | 2.2 | Capitalization | 13.61M |
---|---|---|---|---|---|
Net income 2022 | -73M | Net income 2023 | -37M | EV / Sales 2022 | - |
Net Debt 2022 | 4.59M | Net Debt 2023 | 11.23M | EV / Sales 2023 | 11,278,476 x |
P/E ratio 2022 |
-0.98
x | P/E ratio 2023 |
-0.18
x | Employees | 16 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.69% |
Latest transcript on Seelos Therapeutics, Inc.
1 day | -2.92% | ||
1 week | -23.78% | ||
Current month | -40.41% | ||
1 month | -42.87% | ||
3 months | -83.21% | ||
6 months | -94.79% | ||
Current year | -88.04% |
Managers | Title | Age | Since |
---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 64 | 86-12-31 |
Director of Finance/CFO | 52 | 18-12-31 | |
Karen Fusaro
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 77 | 21-08-31 | |
Richard Pascoe
CHM | Chairman | 60 | 13-02-28 |
Daniel O'Connor
BRD | Director/Board Member | 59 | 18-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 1.39 | +4.51% | 81 548 |
24-05-24 | 1.33 | -2.92% | 100,320 |
24-05-23 | 1.37 | -5.52% | 90,239 |
24-05-22 | 1.45 | -11.04% | 181,409 |
24-05-21 | 1.63 | -6.59% | 112,568 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-88.04% | 3.47M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.66% | 22.1B | |
-9.03% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- SEEL Stock